검색
Urogen Pharma Ltd
URGN관심 목록에 추가
32.720USD
-0.760-2.27%
종가 10-30 16:00（ET）
1.60B시가총액
손실P/E TTM
Urogen Pharma Ltd 정보 회사
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Urogen Pharma Ltd 프로필
종목 코드 URGN
회사 이름Urogen Pharma Ltd
상장일May 04, 2017
CEOBarrett (Elizabeth A)
직원 수235
유형Ordinary Share
회계 연도 종료May 04
주소9 Ha'ta'asiya St
도시RA'ANANA
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Israel
우편 번호4365007
전화97297707601
웹사이트https://www.urogen.com/
종목 코드 URGN
상장일May 04, 2017
CEOBarrett (Elizabeth A)
Urogen Pharma Ltd의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
53.14K
+3.42%
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
53.14K
+3.42%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer
Chief Financial Officer
4.56K
+50.01%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer
Chief Financial Officer
4.56K
+50.01%
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
53.14K
+3.42%
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
53.14K
+3.42%
자주 묻는 질문
Urogen Pharma Ltd의 상위 5대 주주는 누구인가요?
Urogen Pharma Ltd의 상위 5대 주주는 다음과 같습니다: Dr. Arie S. Belldegrun, M.D.
Urogen Pharma Ltd(URGN)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Urogen Pharma Ltd의 주식을 보유한 기관은 총 349곳이며, 이들이 보유한 주식의 총 가치는 약 46.29M로 전체 발행 주식의 95.00%를 차지합니다. 이는 2025Q4 대비 -15691017.00 증가한 수치입니다.
Urogen Pharma Ltd의 최대 수익원은 무엇인가요?
2026Q1 기준, Urogen Pharma Ltd의 Zusduri 부문이 가장 높은 매출을 기록했으며, 금액은 50.43M로 전체 매출의 69.60%를 차지했습니다.